The Risk of Endometrial Malignancy and Other Endometrial Pathology in Women with Abnormal Uterine Bleeding: An Ultrasound-Based Model Development Study by the IETA Group.


Journal

Gynecologic and obstetric investigation
ISSN: 1423-002X
Titre abrégé: Gynecol Obstet Invest
Pays: Switzerland
ID NLM: 7900587

Informations de publication

Date de publication:
2022
Historique:
received: 09 09 2021
accepted: 11 01 2022
pubmed: 14 2 2022
medline: 6 5 2022
entrez: 13 2 2022
Statut: ppublish

Résumé

The aim of this study was to develop a model that can discriminate between different etiologies of abnormal uterine bleeding. The International Endometrial Tumor Analysis 1 study is a multicenter observational diagnostic study in 18 bleeding clinics in 9 countries. Consecutive women with abnormal vaginal bleeding presenting for ultrasound examination (n = 2,417) were recruited. The histology was obtained from endometrial sampling, D&C, hysteroscopic resection, hysterectomy, or ultrasound follow-up for >1 year. A model was developed using multinomial regression based on age, body mass index, and ultrasound predictors to distinguish between: (1) endometrial atrophy, (2) endometrial polyp or intracavitary myoma, (3) endometrial malignancy or atypical hyperplasia, (4) proliferative/secretory changes, endometritis, or hyperplasia without atypia and validated using leave-center-out cross-validation and bootstrapping. The main outcomes are the model's ability to discriminate between the four outcomes and the calibration of risk estimates. The median age in 2,417 women was 50 (interquartile range 43-57). 414 (17%) women had endometrial atrophy; 996 (41%) had a polyp or myoma; 155 (6%) had an endometrial malignancy or atypical hyperplasia; and 852 (35%) had proliferative/secretory changes, endometritis, or hyperplasia without atypia. The model distinguished well between malignant and benign histology (c-statistic 0.88 95% CI: 0.85-0.91) and between all benign histologies. The probabilities for each of the four outcomes were over- or underestimated depending on the centers. Not all patients had a diagnosis based on histology. The model over- or underestimated the risk for certain outcomes in some centers, indicating local recalibration is advisable. The proposed model reliably distinguishes between four histological outcomes. This is the first model to discriminate between several outcomes and is the only model applicable when menopausal status is uncertain. The model could be useful for patient management and counseling, and aid in the interpretation of ultrasound findings. Future research is needed to externally validate and locally recalibrate the model.

Identifiants

pubmed: 35152217
pii: 000522524
doi: 10.1159/000522524
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-61

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Laure Wynants (L)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.

Jan Yvan Jos Verbakel (JYJ)

Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Lil Valentin (L)

Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden.
Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.

Bavo De Cock (B)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

M Angela Pascual (MA)

Department of Obstetrics, Gynecology and Reproduction, Hospital Universitario Dexeus, Barcelona, Spain.

Francesco P G Leone (FPG)

Department of Obstetrics and Gynecology, Biomedical and Clinical Sciences Institute L. Sacco, University of Milan, Milan, Italy.

Povilas Sladkevicius (P)

Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden.

Ruben Heremans (R)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Department of Obstetrics & Gynecology, University Hospital Leuven, Leuven, Belgium.

Juan Luis Alcazar (JL)

Department of Obstetrics and Gynecology, University of Navarra, Pamplona, Spain.

Angelo Votino (A)

Department of Obstetrics and Gynecology, University Hospital Brugmann, Brussels, Belgium.

Robert Fruscio (R)

Clinic of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Milan-Bicocca, San Gerardo Hospital, Monza, Italy.

Elisabeth Epstein (E)

Department of Clinical Science and Education Karolinska Institutet, and Department of Obstetrics and Gynecology, Södersjukhuset, Stockholm, Sweden.

Tom Bourne (T)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Department of Obstetrics and Gynaecology, Imperial College, London, United Kingdom.

Ben Van Calster (B)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.

Dirk Timmerman (D)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Department of Obstetrics & Gynecology, University Hospital Leuven, Leuven, Belgium.

Thierry Van den Bosch (T)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Department of Obstetrics & Gynecology, University Hospital Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH